All Monoclonal Antibodies articles – Page 7
-
NewsRare genetic variant blocks common Alzheimer’s disease risk factor
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
-
News
Utilising CAAR T cells to treat antibody-caused brain disease
Researchers have engineered CAAR T cells to destroy harmful antibodies, improving NMDA receptor encephalitis treatment.
-
WebinarComplete aggregate and particle characterisation of protein, gene and cell therapies
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
-
Whitepaperebook: Maximizing preclinical confidence in target efficacy and safety
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
-
WhitepaperGuide: Screening biologic candidates with nanoDSF
Read this guide about nanoDSF for high-resolution measurements of thermal stability parameters, common CQAs for biologics developability assessment.
-
WhitepaperInfographic: Biologics stability in early development
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
-
NewsImmunotherapy: antibody set for combating tumours
A recent study sheds light on the potential of artificial DNA structures that, when combined with antibodies, guide the immune system to target cancer cells specifically.
-
WebinarBridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
The webinar will explore primary concerns in drug discovery development and why drugs fail.
-
ArticleAddressing the grand challenge of global access to vaccines
Tracy Saveria, James Roberts and Brian Finrow from Lumen Bioscience discuss progress in the aspiration for global vaccine access and how Lumen Bioscience’s inhalation malaria vaccine represents a major step towards it.
-
ArticleRare autoantibody diseases: an innovative targeted pathway
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
-
ArticleAntibody Drug Conjugates: windows of opportunity
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further ...
-
NewsLupus flare-ups linked to bacterial growth in gut
US researchers find that recurrent bouts of systemic lupus erythematosus is closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.
-
NewsNew immunotherapy combination improves efficacy in animal models of liver cancer
Researchers at the Cima University of Navarra lay the foundations for the application of an immunotherapy combination in patients with the liver cancer: hepatocellular carcinoma.
-
WebinarInnovations in organoid modelling for disease modelling and cell therapy
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.
-
NewsPlacenta's role in genetic risk of schizophrenia
A recent study led by the Lieber Institute for Brain Development has revealed that over 100 genes associated with the risk of schizophrenia appear to contribute to the development of the illness primarily through their influence on the placenta.
-
WhitepaperInfographic: Targeted protein degradation
In this infographic, we discuss both inhibition and degradation, the advantages and challenges related to each approach and the key points you need to consider when designing your protein degraders.
-
Whitepaperebook: Quantitative Assays to Measure Ab Binding to Fc Receptors
This ebook summarizes the basics of Fc receptor function and discusses biochemical and cell-based assays that enable antibody optimization projects.
-
NewsCustomising T cell-based immunotherapies to treat cancers
US researchers usings a ‘SNAP’ receptor system can customise immunotherapies for targeted treatments of cancer and other diseases.
-
NewsResident T-cells key to salmonella immunity
According to US researchers, insights from mouse models of salmonella could lead to better vaccines and immunity.
-
Articleebook: Never Miss A Hit - Unleash Your Drug Discovery With A Label-Free Playlist
Get ready to dive into the cutting-edge world of hit-to-lead drug discovery. Look no further than our latest FREE ebook, which explores label-free HTL technologies. Featuring the latest research from leading academics and pharmaceutical companies, including GlaxoSmithKline, Rosalind Franklin Institute and Francis Crick Institute.